- Markets Finally Get Greek Deal —So Where's the Rally?
- 'Mortgage Deal from Hell' Hurts Sound Borrowers: Bove
- Activision Beats on Earnings, Raises Dividend
- Fidelity: 401(k) Balances Little Changed Over 2011
- Are Young American Workers a 'Lost Generation'?
- Westminster’s Most Successful Dog Breeds
- Greek Political Leaders Agree On Austerity Reforms
- Robo-Deal Is All About Lowering Mortgage Principal
- Fed Fines Banks $766 Million Over Mortgage Practices
MOST SHARED
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Investor Optimism At Highest In One Year: Survey
- Markets Get Greece Deal, So Where's the Big Rally?
- How to Get Your Name on the Bathroom Wall 4-EVER
- Indonesia Unexpectedly Cuts Rate to Seek Growth
- Kodak to Stop Making Cameras to Cut Costs
- Robo-Deal Is All About Lowering Mortgage Principal
- The Euro Still Has Room to Rise: Strategist
- Greeks Burn German Flags: Do They Have a Point?
MOST POPULAR
HOT ON FACEBOOK
Genentech Profit Falls Short, but Firm Raises Outlook
Text Size 
Genentech earnings fell short of analysts' expectations, but the company's shares rose slightly in extended trading as the firm lifted its profit forecast for the full year.
 |
AP The Genentech campus in South San Francisco, California. |
Analysts saw the company reporting a profit of 86 cents a share on sales of $3.23 billion, according to Thomson Reuters.
Shares of the company [DNA
Loading...
()
], which lost 3.04 percent to close at $75.39 Monday, were up less than 1 percent.
Genentech, which was seen reporting a full-year profit of between $3.35 and $3.45 a share, said it now expects to earn $3.40 to $3.50 a share.
U.S. sales of Avastin, Genentech's most closely watched product, rose 15 percent to $650 million for the quarter, beating the $643 million expected by analysts, as compiled by Rodman & Renshaw analyst Mike King.
Avastin, used for treating colon and lung cancers, won additional approval earlier this year as a treatment for breast cancer.
Genentech's Sales of Rituxan for non-Hodgkin's lymphoma and rheumatoid arthritis rose 12 percent to $651 million, also outstripping the $630 million expected by Wall Street.
U.S. Sales of breast cancer drug Herceptin rose 3 percent to $338 million for the quarter, falling short of analyst expectations of $345 million.
Net royalty revenue jumped 30 percent to $629 million, helped by favorable foreign exchange rates against the weak dollar. Roche Holding, which owns a majority stake in Genentech and sells its drugs outside the United States, pays royalties in Swiss francs.
Avastin Warning
Separately, Genentech has warned doctors about a type of anemia seen in patients treated with the company's blockbuster cancer drug Avastin in combination with Pfizer's [PFE
Loading...
()
] Sutent in a clinical trial, U.S. regulators said in a notice issued on Monday.
The cases of microangiopathic hemolytic anemia seen in a Phase 1 kidney cancer study led to the closure of a mid-stage trial of Avastin plus Sutent, Genentech said in a letter to doctors that was posted on the Food and Drug Administration's website.
The combination of Avastin plus Sutent is not approved or recommended, the company's letter said.
Avastin, which is approved to treat colon, lung and breast cancer, is widely considered to be Genentech's most important product.
- Reuters contributed to this report.
- Many have called to abolish the Federal Reserve. But what would happen if it was dissolved for good?
- Entrepreneurs have increasingly been buying back their companies over the last three years.
- Where are the best city locations for singles to take the online dating plunge?
- A Steelers fan spent a week with wide receiver Antonio Brown- and it was all due to tweeting.
- Here’s a look at the woman behind the newest collectible toy that kids love.
- Grab a brew—or not—and click ahead to experience the world’s most highly rated beers.
Data is a real-time snapshot *Data is delayed at least 15 minutes
